| Factor Information | |
|---|---|
| Data ID | 2489 |
| Factor | Homocysteine |
| Description | Homocysteine and ADMA levels were higher in the PAH–CHD group (n = 30) than among CHD patients with left-to-right shunting but no PAH (n = 20; P<0.001) and healthy control subjects (n = 20; P<0.001). |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | diagnosis |
| Objective | This study was designed to determine biomarker levels in patients with PAH associated with CHD (PAH–CHD) and CHD patients without PAH and to investigate the relationship of these potential biomarkers with hemodynamic findings |
| p Value | <0.001 |
| Conclusion | These parameters have the potential to be used as biomarkers in the diagnosis and follow-up evaluation of patients with PAH–CHD. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 605 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | VSD/TA/PDA/ASD/DORV, MA/LTRS |
| Reference | |
|---|---|
| PMID | 22526220 |
| Year | 2012 |
| Title | Elevated homocysteine and asymmetric dimethyl arginine levels in pulmonary hypertension associated with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | All | |
| Source | Plasma | |
| Region | Kirikkale, Turkey | |
| Method | Cardiac catheterization and echocardiographs were performed; Plasma homocysteine, asymmetric dimethyl arginine (ADMA), and nitric oxide (NO) levels were determined by enzymelinked immunosorbent assay. | |
| Race | European | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | PAH–CHD group(Treatment) | CHD patients with left-to-right shunting but no PAH(Control) |
| Number | 30 | 20 |
| Age | 128.3 ± 87 (12 mos–26 years) months | 104.2 ± 58 (2 mos–16 years) months |
| Gender (Male: Female) | 15:15 | 8:12 |
| Marker Level | 20.5 ± 5.2 μmol/L | 14.5 ± 2.6 μmol/L |
